Emergent drug resistance with integrase strand transfer inhibitor-based regimens

AIDS

Volumn 31, Issue 10, 2017, Pages 1425-1434

  Lepik, Katherine J ^a   Harrigan, P Richard ^a,b   Yip, Benita ^a   Wang, Lu ^a   Robbins, Marjorie A ^a,b   Zhang, Wendy W ^a   Toy, Junine ^a   Akagi, Linda ^a   Lima, Viviane D ^a,b   Guillemi, Silvia ^a   Montaner, Julio S G ^a,b   Barrios, Rolando ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

dolutegravir; drug resistance; elvitegravir; HIV integrase inhibitors; raltegravir

Indexed keywords

CD4 ANTIGEN; DOLUTEGRAVIR; ELVITEGRAVIR; INTEGRASE INHIBITOR; INTEGRASE STRAND TRANSFER INHIBITOR; RALTEGRAVIR; UNCLASSIFIED DRUG;

ADULT; ALGORITHM; ANTIRETROVIRAL THERAPY; ARTICLE; BRITISH COLUMBIA; COHORT ANALYSIS; DRUG RESISTANCE; FEMALE; HAZARD RATIO; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; VIRUS MUTATION; VIRUS RESISTANCE; ANTIVIRAL RESISTANCE; EPIDEMIOLOGY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MIDDLE AGED; MISSENSE MUTATION; VIROLOGY;

ADULT; BRITISH COLUMBIA; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MUTATION, MISSENSE; RETROSPECTIVE STUDIES;

EID: 85017154145     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000001494     Document Type: Article

References (36)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services; 2016, Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf [Accessed February 2016].
2. European AIDS Clinical Society (EACS). Guidelines v.8. ECAS, Brussels, Belgium; 2015. Available at: http://www.eacsociety.org/files/guidelines-8.0-english.pdf [Accessed May 2016].
3. Gunthard HF, Saag MS, Benson CA, del Rio C, Eron JJ, Gallant JE, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society-USA Panel. JAMA 2016; 316:191-210.
4. Montaner J, Guillemi S, Harris M. Therapeutic guidelines for antiretroviral (ARV) treatment of adult HIV infection. British Columbia Centre for Excellence in HIV/AIDS, Vancouver Canada; 2015. Available at http://www.cfenet.ubc.ca/therapeuticguidelines/adult. [Accessed May 2016].
5. Lennox JL, DeJesus E, Lazzarin A, Pollard RB, Madruga JV, Berger DS, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatmentnaive patients with HIV-1 infection: a multicentre, doubleblind randomised controlled trial. Lancet 2009; 374: 796-806.
6. DeJesus E, Rockstroh JK, Henry K, Molina JM, Gathe J, Ramanathan S, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavirboosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, noninferiority trial. Lancet 2012; 379:2429-2438.
7. Sax PE, DeJesus E, Mills A, Zolopa A, Cohen C, Wohl D, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012; 379:2439-2448.
8. Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, noninferiority SPRING-2 study. Lancet 2013; 381:735-743.
9. Clotet B, Feinberg J, van Lunzen J, Khuong-Josses MA, Antinori A, Dumitru I, et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet 2014; 383:2222-2231.
10. Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutierrez F, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med 2013; 369:1807-1818.
11. Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, noninferiority SAILING study. Lancet 2013; 382:700-708.
12. Martinez E, Larrousse M, Llibre JM, Gutierrez F, Saumoy M, Antela A, et al. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS 2010; 24:1697-1707.
13. Molina JM, Lamarca A, Andrade-Villanueva J, Clotet B, Clumeck N, Liu YP, et al. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatmentexperienced patients with HIV-1 receiving a ritonavirboosted protease inhibitor: randomised, double-blind, phase 3, noninferiority study. Lancet Infect Dis 2012; 12: 27-35.
14. Martin K, Begaud B, Latry P, Miremont-Salame G, Fourrier A, Moore N. Differences between clinical trials and postmarketing use. Br J Clin Pharmacol 2004; 57:86-92.
15. Drug resistance emerging during therapy with dolutegravir and other integrase inhibitors. Lepik KJ, Barrios R, editors. Pharmacovigilance initiative safety alert no 5 Vancouver, Canada: BC Centre for Excellence in HIV/AIDS; 2015. Available at http://www.cfenet.ubc.ca/hiv-drug-safety [Accessed May 2016].
16. Patterson S, Cescon A, Samji H, Cui Z, Yip B, Lepik KJ, et al. Cohort profile: HAART observational medical evaluation and research (HOMER) cohort. Int J Epidemiol 2015; 44:58-67.
17. BC Centre for Excellence in HIV/AIDS, Drug treatment program and laboratory program. BC Centre for Excellence in HIV/AIDS, Vancouver, Canada. Available at http://www.cfenet.ubc.ca/drug-treatment-program and http://www.cfenet.ubc.ca/research/laboratory-program [Accessed May 2016].
18. Stanford University, HIV Drug Resistance Database version 7.0.1, Stanford University, Stanford USA; 2014. Available at http://sierra2. stanford.edu/sierra/servlet/JSierra. [Accessed November 2015].
19. Liu TF, Shafer RW. Web resources for HIV type 1 genotypicresistance test interpretation. Clin Infect Dis 2006; 42:1608-1618.
20. McGovern RA, Woods CK, Brumme CJ, Chan D, Hogg RS, Montaner JS, et al. Low incidence of integrase inhibitor failure and resistance in HIV-1 infected patients in British Columbia. [Abstract O034]. 21st Annual Canadian Conference on HIV/AIDS Research (CAHR). 19-22 April 2012.
21. Lima VD, Harrigan R, Murray M, Moore DM, Wood E, Hogg RS, et al. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals. AIDS 2008; 22:2371-2380.
22. Gonzalez-Serna A, Min JE, Woods C, Chan D, Lima VD, Montaner JS, et al. Performance of HIV-1 drug resistance testing at low-level viremia and its ability to predict future virologic outcomes and viral evolution in treatment-naive individuals. Clin Infect Dis 2014; 58:1165-1173.
23. Swenson LC, Min JE, Woods CK, Cai E, Li JZ, Montaner JS, et al. HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failure. AIDS 2014; 28:1125-1134.
24. Woods CK, Brumme CJ, Liu TF, Chui CK, Chu AL, Wynhoven B, et al. Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool. J Clin Microbiol 2012; 50:1936-1942.
25. Lin DY. Cox regression analysis ofmultivariate failure time data: the marginal approach. Stat Med 1994; 13:2233-2247.
26. Lima VD, Bangsberg DR, Harrigan PR, Deeks SG, Yip B, Hogg RS, et al. Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level. J Acquir Immune Defic Syndr 2010; 55: 460-465.
27. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994; 81:515-526.
28. Mesplede T, Wainberg MA. Resistance against integrase strand transfer inhibitors and relevance to HIV persistence. Viruses 2015; 7:3703-3718.
29. Fulcher JA, Du Y, Sun R, Landovitz RJ. Emergence of integrase resistance mutations during initial therapy with TDF/FTC/DTG [Abstract 500LB]. Conference on Retroviruses and Opportunistic Infections (CROI). 13-16 Feb. 2017.
30. Trottier B, Lake J, Logue K, Brinson C, Santiago L, Brennan C, et al. Switching to abacavir/dolutegravir/lamivudine fixed dose combination (ABC/DTG/3TC FDC) from a PI, INI, or NNRTI base regimen maintains HIV suppression. [Abstract]. 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). 17-21 Sep. 2015.
31. Lake J, Trottier B, Garcia-Diaz J, Edelstein H, Kumar P, Bredeek UF, et al. STRIIVING: Switching to abacavir/dolutegravir/lamivudine fixed dose combination (ABC/DTG/3TC FDC) from a PI, NNRTI or INI-based regimen maintains HIV suppression at week48. [Abstract 137]. Australasian HIV & AIDS Conference. 16-18 Nov. 2016.
32. Mollan K, Daar ES, Sax PE, Balamane M, Collier AC, Fischl MA, et al. HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status. J Infect Dis 2012; 206:1920-1930.
33. Pinoges L, Schramm B, Poulet E, Balkan S, Szumilin E, Ferreyra C, et al. Risk factors and mortality associated with resistance to firstline antiretroviral therapy: multicentric cross-sectional and longitudinal analyses. J Acquir Immune Defic Syndr 2015; 68:527-535.
34. Teno Res Study Group. Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. Lancet Infect Dis 2016; 16:565-575.
35. Lam WY, Fresco P. Medication adherence measures: an overview. Biomed Res Int 2015; 2015:217047.
36. Eron JJ, Young B, Cooper DA, Youle M, Dejesus E, Andrade-Villanueva J, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010; 375:396-407.